Navigation Links
Statement from the Consumer Healthcare Products Association on Today's Joint FDA Advisory Committee Recommendations Regarding Pediatric Over-the-Counter Cough and Cold Medicines
Date:10/19/2007

WASHINGTON, Oct. 19 /PRNewswire-USNewswire/ -- Following is a statement by Linda A. Suydam, D.P.A., president of the Consumer Healthcare Products Association (CHPA), regarding the recommendations issued today by the U.S. Food and Drug Administration's Nonprescription Drugs Advisory Committee and Pediatric Advisory Committee. At a meeting this week, the joint committee addressed the use of over-the-counter cough and cold medicines in children.

"For decades, parents and other caregivers have relied upon and trusted pediatric cough and cold medicines to relieve symptoms of the common cold in children and provide real comfort to children with runny noses, congestion and coughs.

"We believe that some of today's advisory committee recommendations support and confirm the risk-management efforts we have proposed. However, other recommendations -- notably the split vote to make single active ingredients no longer available for use in children under six years old -- if adopted by FDA, would unduly limit parents' access to medicines that work and are safe when taken as directed. The committee's split majority vote on this matter clearly did not reflect a consensus of opinion, and we hope the FDA will weigh this recommendation with great caution. Adoption of this recommendation would leave parents with no over-the-counter medicinal relief when their children are suffering from cold symptoms.

"The data clearly show that these medicines are very safe when used as directed and that harm to this age group, while very rare, is attributable in most cases to accidental ingestion -- an issue of safekeeping that is best addressed through education.

"Over-the-counter cough and cold medicines with multiple ingredients play an important role in relieving suffering from the common cold. It is easier and more practical to treat a child with a multiple symptom relief product. And the data presented at the advisory committee meeting show that multiple-ingredient products are as safe if not even less susceptible to misuse.

"Today, the advisory committee decided that there was insufficient evidence in pediatric populations to support efficacy. This is an issue we will address with FDA. We are already planning pharmacokinetic studies in children, which are the first step toward confirming correct dosing, and we will work with FDA to design appropriate pediatric clinical efficacy studies."

CHPA is the 126-year-old trade association representing U.S. manufacturers and distributors of over-the-counter medicines and nutritional supplement products.

http://www.chpa-info.org


'/>"/>
SOURCE Consumer Healthcare Products Association
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
2. Iodex goes to SmithKline Beecham consumer Healthcare
3. Consumer group seeks Sibutramine ban
4. Identifying What Consumers Look For On Food Stuff Labels
5. Consumers Becoming More Health Conscious Than Calorie Conscious
6. With More Appearance Conscious Consumers The Need For Slimming Products Is Rapidly Rising
7. Consumers of soft drinks to be more alert
8. Consumers Worried About Trans-Fats The Most
9. New Plastic Surgery Unit Set Up In Kolkata To Meet Ever-Increasing Consumer Demand
10. Health care system “Consumer friendly” by 207
11. Chocolate makers to be health wise and urge consumers to be too!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: